Before the shelf, the essentials: what haemophilia is, how each bleed site behaves, and the doctrine, treatment and Singapore rules a bleed-guidance tool has to respect. Then the documents themselves: World Federation of Hemophilia guidelines, national emergency-medicine protocols, peer-reviewed evidence, and Singapore's own institutional and government sources. Each entry links to its official source, never a rehosted copy, with a short note on what the project takes from it. The full claim-level knowledge base sits in the repo; this page is the annotated shelf it was built from.
The clinical ground this project stands on, condensed to what a bleed-guidance tool has to respect. A reference primer, not medical advice: care decisions belong with the treatment centres.
Haemophilia is an inherited bleeding disorder: the blood is missing, or does not have enough of, a clotting factor, so it cannot form a stable clot. Haemophilia A (a shortage of factor VIII) is three to four times more common than haemophilia B (factor IX); the two look identical in a patient but need different treatment products. A person with haemophilia does not bleed faster than anyone else, but bleeding takes longer to stop and can restart days later, so most small cuts still stop with ordinary first aid: the real concern is bleeding nobody can see, into a joint or muscle, or after a bigger injury. Both genes sit on the X chromosome, so haemophilia affects mostly males, and roughly 30% of cases arise with no family history at all.
Can bleed spontaneously, without an obvious injury, most often into joints and muscles.
Usually bleeds after an injury, with occasional spontaneous bleeds.
Bleeds mainly after significant trauma, surgery or dental work, sometimes not diagnosed until adulthood.
Three centres treat haemophilia here: Singapore General Hospital (adults), KK Women's and Children's Hospital (children), and National University Hospital (both). Recombinant factor VIII sits on MOH's Standard Drug List (50 to 75% subsidy), and from October 2025 MediShield Life covers haemophilia A and B treatment as a high-cost outpatient drug, on top of HSS's own S$400 to $1,200 a month subsidy.
With modern treatment started early, people with severe haemophilia in a well-resourced system like Singapore's can expect a near-normal lifespan.
This primer condenses the WFH Guidelines, MASAC 257, and Singapore's institutional sources in the library below; its plain-language facts on what haemophilia is and how it is inherited also draw on the NIH NHLBI, National Bleeding Disorders Foundation, NHS UK, NORD and MedlinePlus Genetics fact sheets on haemophilia A and B.
The clinical backbone of the whole project. Almost every claim in the Haemophilia 101 primer above, its severity bands, bleed-site doctrine, and treatment sections, traces to these three documents.
World Federation of Hemophilia (Srivastava et al.), published in Haemophilia
The project's clinical spine: severity band definitions (severe under 1%, moderate 1 to 5%, mild 5 to 40%), Chapter 6 prophylaxis doctrine, and Chapter 7's site-specific bleed treatment rules (treat on suspicion, factor before imaging). Also the source for Chapter 8 on inhibitors and Chapter 10 on musculoskeletal complications and target-joint damage.
World Federation of Hemophilia
Sets emergency-department operational standards alongside MASAC 257: factor concentrate available within one hour of arrival, urgent triage category, and treatment based on history rather than waiting for consult or imaging. Underpins the case files' "one-hour ED target" and this page's doctrine list.
World Federation of Hemophilia
The source of the roughly 280 Singapore patient count (230 with haemophilia A, 50 with haemophilia B) used throughout the case files and solution files, including the age split showing 42% of haemophilia A patients are 45 or older.
The two documents that set the "treat first, test later" rule the whole off-hours case rests on, and the one national ED protocol Singapore does not have an equivalent to.
National Bleeding Disorders Foundation (MASAC)
Source of the doctrine that structures the case files and this page's Haemophilia 101 primer: treat first, test later; factor before imaging; assume 0% factor level if unknown; and the one-hour target for factor availability in the emergency department.
Royal College of Emergency Medicine, UK
A national, published, best-practice guideline for treating haemophilia patients in a general emergency department. Cited throughout the case files' gap map as the international precedent Singapore has no published equivalent to: no Singapore ED publishes a haemophilia protocol, fast-track, or alert-card scheme.
The peer-reviewed papers behind the site's sharpest numbers: severity and target-joint definitions, ED delay data from two health systems, the strongest home-management result found, and the negative evidence against generic symptom checkers.
Blanchette et al., International Society on Thrombosis and Haemostasis, Journal of Thrombosis and Haemostasis
The formal source for severity bands (severe under 1%, moderate 1 to 5%, mild 5 to 40%) and the target-joint definition (three or more spontaneous bleeds into one joint within six months) used across this page's Haemophilia 101 primer and the clinical knowledge base.
Littner, Thomas, Mooney, Doyle, Hendrickson, Tarango, Pediatric Blood & Cancer
The Cincinnati Children's Hospital quality-improvement study behind the 110-to-42-minute time-to-factor figure quoted in the case files, explicitly labelled a US benchmark rather than a confirmed Singapore statistic, since no Singapore time-to-factor data has been published.
Uminski, Rydz, Goodyear, presented at ASH 2023, published in Blood
A Canadian audit of 393 emergency-department visits by 191 haemophilia patients, finding time to haemostatic treatment fell outside care standards. Supports the case files' argument that ED-side delay is a current, unresolved problem even in systems with named treatment centres.
Merrill, Webber, Merrill, Shmookler, Research and Practice in Thrombosis and Haemostasis
A rural US Hemophilia Treatment Center's quality-improvement project: preventable emergency-department visits fell 83% and annual clotting-factor cost per patient fell by more than $11,000, saving the system roughly $982,000 a year. The strongest evidence found for the case files' argument that support at home is the intervention point that moves outcomes the most.
npj Digital Medicine (Nature)
A systematic review finding generic symptom checkers had 19 to 38% diagnostic accuracy and real, documented safety failures. The safety case's negative evidence: it is the strongest argument in the research base for why a haemophilia-specific tool must stay narrow rather than becoming a general triage app.
Blood (American Society of Hematology)
The pooled mortality and incidence figures behind the case files' asymmetry ledger: roughly 20 to 34% mortality from intracranial haemorrhage, with about half of survivors left permanently disabled.
The Haemophilia Society of Singapore's own research and reporting, the closest thing this project has to a client brief.
Haemophilia Society of Singapore, with Blackbox Research
Shared directly with the project team by HSS: source of the "resilience burden" framing in the case files' scale section, the 85% bled-last-year and six-breakthrough-bleeds-a-year figures, and the verbatim rationing quote ("I will actually delay my Factor VIII treatment to see if the bleed can contain itself"). Also source of the S$7,004 average annual family burden and HSS's own aspiration for "a centralised information hub offering clear, consistent treatment, escalation, and care-planning resources," the direct mandate this project treats PS2 as answering.
Haemophilia Society of Singapore
The source for Singapore's three treatment centres, HSS's own monthly subsidy caps (S$400 to S$1,200 depending on product and age group), the factor-cost anchors (a bottle above S$100, an ankle bleed consuming up to six bottles), and the funding order of government subsidy, then MediShield Life, then MediSave, then HSS aid.
Haemophilia Society of Singapore
Confirms HSS runs with zero paid staff, spends the large majority of its budget on treatment subsidies (95% in FY2021/22), and states plainly that it "promotes home treatment." Source of the finding that HSS has no capacity to staff an after-hours hotline, a hard constraint on any solution that assumes HSS as an operating partner.
The public record of Singapore's actual care pathway, hospital by hospital and agency by agency, mapped fact by fact for the case files' gap map.
SingHealth
The only published after-hours instruction found anywhere in the Singapore haemophilia care system: after hours, go to the KKH Children's Emergency Department and notify the Haematology Resource Nurse the next working day. Also carries the "if in doubt, treat" line and the one-to-two-hour treatment window quoted across the site.
KK Women's and Children's Hospital
Confirms Children's Emergency runs 24 hours. U-PAL, KKH's free advice service, has been rebuilt with generative AI and now operates around the clock, covering common paediatric conditions in children under 18, though it tells families whose child has a chronic condition needing ongoing specialist follow-up to consult their care team instead. Cited as proof the model works in Singapore, and that it does not yet cover haemophilia or anyone over 18.
Singapore General Hospital
Source of the finding that SGH's urgent factor walk-in service for adults is office hours only, Monday to Friday 8am to 6pm and Saturday 8am to 1pm, closed Sunday and public holidays. The basis for the case files' claim that the adult treatment centre offers no overnight option at all.
National University Hospital
Source for NUH's paediatric and adult haematology pathway, home-therapy training including Portacath support for children with difficult venous access, and the local phrasing of the treat-within-one-to-two-hours doctrine.
Ministry of Health
Confirms NurseFirst's nationwide six-month trial from June 2025, its 8am to 11pm hours, and its role as a generalist triage layer not protocolised for rare disorders. Cited as evidence that MOH is already building assessed triage layers, the system direction a haemophilia-specific tool would sit inside.
Ministry of Health
Describes the programme that produced a 36 to 40% drop in self-referred walk-in emergency attendances at Changi General Hospital by pairing GP referral with a fee offset and queue priority. The behavioural precedent the case files cites for why "following the advice buys the family something concrete" changes escalation behaviour.
Singapore Civil Defence Force
Source of the 995 ambulance policy: free when SCDF assesses a conveyed case as a genuine emergency, a flat S$274 fee if it assesses the case as non-emergency. One half of the case files' asymmetric-cost ledger.
Ministry of Health
The official public wait-time dataset for Singapore's restructured hospital emergency departments, and the source for the finding that no P3 (ambulant, minor) wait-to-consultation figures are published, the exact triage category an early joint bleed is likely to fall into.
The rules any tool built on this research would have to satisfy: software-as-a-medical-device classification, insurance coverage, and drug-formulary status.
Health Sciences Authority
Sets the classification a patient- or caregiver-facing bleed-escalation tool would likely fall under: a regulated Software as a Medical Device, Class B or C, since the clinical decision support exemption applies only when a healthcare professional is the end user. HSA's guidance-document URLs move; link to the current guidance-documents index rather than a specific PDF.
Ministry of Health, with the MediShield Life Scheme Act subsidiary legislation
Confirms MediShield Life expanded from 1 October 2025 to cover haemophilia A and B treatment as a designated high-cost outpatient drug, a major, recent policy change cited in this page's Singapore layer.
National Drug Formulary
Confirms recombinant factor VIII products sit on MOH's Standard Drug List carrying 50 to 75% subsidy depending on means-testing, and gives emicizumab's separate formulary status, the basis for this page's "on the SDL" note above.
This is a curated shelf of primary documents. The complete claim-level knowledge base, every clinical claim traced to a specific whitelisted source with the exact page or chapter cited, is kept with the project research notes, including the clinical knowledge base and the Singapore-context, problem-clarity and clinical-evidence files. The site's other two pages, the case files and the solution files, cite into these documents; this page, its Haemophilia 101 primer included, names the documents themselves.
A HackitRx 2026 entry by AuraHack: Ariel Tan, Rachel Koh, Myo Myo Swe Oo and Gerald Ho. See the team.
Every link on this page was checked for a live response in August 2026. Compiled 31 Aug 2026 for HackitRx 2026 research. Companion to the problem statement files and the solution files. Illustrations AI-generated (Codex CLI), art-directed to the Patient Files design system.
